NCT06761989 Intrathecal Morphine Injection Versus Continuous Wound Infiltration After Pancreaticoduodenectomy
| NCT ID | NCT06761989 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seoul National University Hospital |
| Condition | Pain Management |
| Study Type | INTERVENTIONAL |
| Enrollment | 104 participants |
| Start Date | 2025-01-15 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 104 participants in total. It began in 2025-01-15 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective randomized open-label noninferiority trial that compares intrathecal morphine injection and continuous wound infiltration after open pancreaticoduodenectomy.
Eligibility Criteria
Inclusion Criteria: * Adults 19 years of age or older * Scheduled for elective open pancreaticoduodenectomy or pylorus preseriving pancreaticoduodenectomy * Disease of periampullary lesions * Perfromance status assessed with ECOG score is 0 or 1 at the time of enrollment * Able to provide written informed consent to participate in the study, understand the procedures of this study, and complete patient-reported questionnaires * American Society of Anesthesiologists physical status I to III Exclusion Criteria: * Hypersensitivity to medications used for pain control (fentanyl, ropivacaine, morphine, acetaminophen, NSAIDs) * Cognitive impairment that affects using patient-controlled analgesia device or answering patient-reported questionnaires * Infection or anatomical abnormalities of the abdominal wall and skin that preclude catheterization for continuous wound infiltration * Contraindicated for intrathecal injection due to any coagulation disorder or continued use of anticoagulants * Have a major medical or psychiatric illness that would affect response to treatment * History of chronic pain, or chronic use of analgesics or psychiatric medications * Have severe liver or kidney disease * Anyone who are not appropriate for the study in the opinion of the investigators
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06761989 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Pain Management. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06761989 currently recruiting?
Yes, NCT06761989 is actively recruiting participants. Contact the research team at hjpainfree@snu.ac.kr for enrollment information.
Where is the NCT06761989 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06761989 clinical trial?
NCT06761989 is sponsored by Seoul National University Hospital. The trial plans to enroll 104 participants.